Skip to main content
Top
Published in: AIDS and Behavior 3/2019

01-10-2019 | Human Immunodeficiency Virus | Original Paper

PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA

Authors: Charlotte-Paige Rolle, Udodirim Onwubiko, Jennifer Jo, Anandi N. Sheth, Colleen F. Kelley, David P. Holland

Published in: AIDS and Behavior | Special Issue 3/2019

Login to get access

Abstract

For marginalized populations, county health departments may be important PrEP access points; however, there are little data on successful PrEP programs at these venues outside of incentivized demonstration projects. Therefore, we implemented an open-access, free PrEP clinic at a county health department in Atlanta, GA to promote PrEP uptake among high-risk clients. The Fulton County Board of Health PrEP clinic launched in October 2015, and eligible clients who expressed interest initiated PrEP and attended follow-up visits per CDC guidelines. Clients engaged in quarterly follow-up and seen within the last 6 months were defined as “persistent”, whereas clients with a lapse in follow-up of > 6 months were defined as “not persistent.” Factors associated with PrEP persistence were assessed with unadjusted odds ratios. Between October 2015 and June 2017, 399 clients were screened for PrEP, almost all were eligible [392/399 (98%)]; however, 158/392 (40%) did not return to start PrEP after screening. Of 234 patients, 216 (92%) received a prescription for PrEP. As of June 2017, only 69/216 (32%) clients remained persistent in PrEP care, and the only evaluated factor significantly associated with PrEP persistence was age ≥ 30 years (OR 1.86, 95% CI 1.02, 3.42). Implementation of PrEP in the county health department setting is feasible; however, we have identified significant challenges with PrEP uptake and persistence in our setting. Further research is needed to fully understand mediators of PrEP persistence and inform interventions to optimize health department-based PrEP services.
Literature
6.
go back to reference Rendina HJ, et al. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the US. Soc Sci Med. 2017;172:115–23.CrossRefPubMed Rendina HJ, et al. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the US. Soc Sci Med. 2017;172:115–23.CrossRefPubMed
7.
go back to reference Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in pre-exposure prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12(2):e0172354.CrossRefPubMedPubMedCentral Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in pre-exposure prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12(2):e0172354.CrossRefPubMedPubMedCentral
8.
go back to reference Hoots BE, et al. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men-20 US cities, 2014. Clin Infect Dis. 2016;63(5):672–7.CrossRefPubMedPubMedCentral Hoots BE, et al. Willingness to take, use of, and indications for pre-exposure prophylaxis among men who have sex with men-20 US cities, 2014. Clin Infect Dis. 2016;63(5):672–7.CrossRefPubMedPubMedCentral
10.
go back to reference Siegler AJ, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMed Siegler AJ, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMed
11.
12.
go back to reference Siegler AJ, et al. Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States. Ann Epidemiol. 2018;28(12):858–64.CrossRefPubMed Siegler AJ, et al. Location location location: an exploration of disparities in access to publicly listed pre-exposure prophylaxis clinics in the United States. Ann Epidemiol. 2018;28(12):858–64.CrossRefPubMed
13.
go back to reference Ojikutu BO, et al. Spatial access and willingness to use pre-exposure prophylaxis among Black/African American individuals in the United States: cross-sectional survey. JMIR Public Health Surveill. 2019;5(1):e12405.CrossRefPubMedPubMedCentral Ojikutu BO, et al. Spatial access and willingness to use pre-exposure prophylaxis among Black/African American individuals in the United States: cross-sectional survey. JMIR Public Health Surveill. 2019;5(1):e12405.CrossRefPubMedPubMedCentral
14.
go back to reference Rolle CP, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. J Acquir Immune Defic Syndr. 2017;76(3):250–8.CrossRefPubMedPubMedCentral Rolle CP, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. J Acquir Immune Defic Syndr. 2017;76(3):250–8.CrossRefPubMedPubMedCentral
15.
go back to reference Rusie LK, et al. PrEP initiation and retention in care over five years, 2012-2017: are quarterly visits too much? Clin Infect Dis. 2018;67:283–7.CrossRefPubMed Rusie LK, et al. PrEP initiation and retention in care over five years, 2012-2017: are quarterly visits too much? Clin Infect Dis. 2018;67:283–7.CrossRefPubMed
16.
go back to reference Doblecki-Lewis S, et al. Patterns and correlates of participant retention in a multi-city pre-exposure prophylaxis demonstration project. J Acquir Immune Defic Syndr. 2018;79:62–9.CrossRefPubMedPubMedCentral Doblecki-Lewis S, et al. Patterns and correlates of participant retention in a multi-city pre-exposure prophylaxis demonstration project. J Acquir Immune Defic Syndr. 2018;79:62–9.CrossRefPubMedPubMedCentral
17.
go back to reference Chan PA, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.CrossRefPubMedPubMedCentral Chan PA, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.CrossRefPubMedPubMedCentral
18.
go back to reference Hojilla JC, et al. HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav. 2018;22(4):1096–9.CrossRefPubMedPubMedCentral Hojilla JC, et al. HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav. 2018;22(4):1096–9.CrossRefPubMedPubMedCentral
19.
go back to reference Grinsztejn B, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–45.CrossRefPubMed Grinsztejn B, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–45.CrossRefPubMed
20.
go back to reference Huang YA, Tao G, Smith DK, Hoover KW. Persistence with HIV preexposure prophylaxis in the United States, 2012-2016. In: Conference on retroviruses and opportunistic infections, March 4–7, 2019, Seattle, WA, Abstract 106. Huang YA, Tao G, Smith DK, Hoover KW. Persistence with HIV preexposure prophylaxis in the United States, 2012-2016. In: Conference on retroviruses and opportunistic infections, March 4–7, 2019, Seattle, WA, Abstract 106.
21.
go back to reference Coy KC, et al. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22(2):e25252.CrossRefPubMedPubMedCentral Coy KC, et al. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22(2):e25252.CrossRefPubMedPubMedCentral
22.
go back to reference Serota DP, Rosenberg ES, Thorne AL, del Rio C, Luisi N, et al. PrEP persistence and discontinuation in a Cohort of young black men who have sex with men in Atlanta, GA. In: Conference on retroviruses and opportunistic infections (CROI), March 4–7, 2019, Seattle, WA, Abstract 963. Serota DP, Rosenberg ES, Thorne AL, del Rio C, Luisi N, et al. PrEP persistence and discontinuation in a Cohort of young black men who have sex with men in Atlanta, GA. In: Conference on retroviruses and opportunistic infections (CROI), March 4–7, 2019, Seattle, WA, Abstract 963.
23.
go back to reference White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States updated to 2020 (2015). White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States updated to 2020 (2015).
24.
go back to reference Weiss G, et al. PrEP implementation by local health departments in US cities and counties: findings from a 2015 assessment of local health departments. PLoS ONE. 2018;13(7):e0200338.CrossRefPubMedPubMedCentral Weiss G, et al. PrEP implementation by local health departments in US cities and counties: findings from a 2015 assessment of local health departments. PLoS ONE. 2018;13(7):e0200338.CrossRefPubMedPubMedCentral
26.
go back to reference Liu AY, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral Liu AY, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176(1):75–84.CrossRefPubMedPubMedCentral
27.
go back to reference Marcus JL, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–6.CrossRefPubMedPubMedCentral Marcus JL, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–6.CrossRefPubMedPubMedCentral
28.
go back to reference Centers for Disease Control and Prevention. Social determinants of health and selected HIV care outcomes among adults with diagnosed HIV infection in 32 states and the District of Columbia, 2014. HIV Surveill Suppl Rep. 2016;21(7):1–62. Centers for Disease Control and Prevention. Social determinants of health and selected HIV care outcomes among adults with diagnosed HIV infection in 32 states and the District of Columbia, 2014. HIV Surveill Suppl Rep. 2016;21(7):1–62.
29.
go back to reference Blackstock OJ, et al. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866–9.CrossRefPubMedPubMedCentral Blackstock OJ, et al. Pre-exposure prophylaxis prescribing and retention in care among heterosexual women at a community-based comprehensive sexual health clinic. AIDS Care. 2017;29(7):866–9.CrossRefPubMedPubMedCentral
30.
go back to reference Hosek S, et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.CrossRefPubMedPubMedCentral Hosek S, et al. An HIV pre-exposure prophylaxis (PrEP) demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.CrossRefPubMedPubMedCentral
31.
go back to reference Sullivan PS, et al. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep. 2019;16:259–69.CrossRefPubMed Sullivan PS, et al. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep. 2019;16:259–69.CrossRefPubMed
32.
go back to reference Siegler AJ, Brock JB, Kelley CF, Ahlschlager LA, Rolle CPM, et al. Pilot test of a PrEP telmedicine system for young black MSM in the rural US South. In: Conference of retroviruses and opportunistic infections (CROI), March 4–7, 2019, Seatlle, WA, Abstract 955. Siegler AJ, Brock JB, Kelley CF, Ahlschlager LA, Rolle CPM, et al. Pilot test of a PrEP telmedicine system for young black MSM in the rural US South. In: Conference of retroviruses and opportunistic infections (CROI), March 4–7, 2019, Seatlle, WA, Abstract 955.
33.
go back to reference Marcus JL, et al. Disparities in uptake of HIV preexposure prophylaxis in a large integrated health care system. Am J Public Health. 2016;106(10):e2–3.CrossRefPubMedPubMedCentral Marcus JL, et al. Disparities in uptake of HIV preexposure prophylaxis in a large integrated health care system. Am J Public Health. 2016;106(10):e2–3.CrossRefPubMedPubMedCentral
34.
go back to reference Jenness S, Maloney K, Smith DK, Hoover KW, Goodreau SM, Weiss K, Rosenberg ES, Sullivan PS. The PrEP care continuum and HIV racial disparities among men who have sex with men. In: Conference on retroviruses and opportunistic infections (CROI), March 4–7, 2018, Boston, MA, Abstract 1149. Jenness S, Maloney K, Smith DK, Hoover KW, Goodreau SM, Weiss K, Rosenberg ES, Sullivan PS. The PrEP care continuum and HIV racial disparities among men who have sex with men. In: Conference on retroviruses and opportunistic infections (CROI), March 4–7, 2018, Boston, MA, Abstract 1149.
35.
go back to reference Giler Mera R, Magnuson D, Trevor H, Bush S, Rawlings K, McCallister S. Changes in truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012-2016). In: 19th IAS conference on HIV science, 23–26 July 2017, Paris, France, Abstract 1614. Giler Mera R, Magnuson D, Trevor H, Bush S, Rawlings K, McCallister S. Changes in truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States: (2012-2016). In: 19th IAS conference on HIV science, 23–26 July 2017, Paris, France, Abstract 1614.
37.
go back to reference Flash CA, et al. Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS. 2014;28(12):635–42.CrossRefPubMedPubMedCentral Flash CA, et al. Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDS. 2014;28(12):635–42.CrossRefPubMedPubMedCentral
38.
go back to reference Hong JN, Farel CE, Rahangdale L. Pharmacologic prevention of human immunodeficiency virus in women: practical approaches for the obstetrician and gynecologist. Obstet Gynecol Surv. 2015;70(4):284–90.CrossRefPubMed Hong JN, Farel CE, Rahangdale L. Pharmacologic prevention of human immunodeficiency virus in women: practical approaches for the obstetrician and gynecologist. Obstet Gynecol Surv. 2015;70(4):284–90.CrossRefPubMed
39.
go back to reference Doblecki-Lewis S, et al. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS. 2016;27(10):873–81.CrossRefPubMed Doblecki-Lewis S, et al. HIV risk and awareness and interest in pre-exposure and post-exposure prophylaxis among sheltered women in Miami. Int J STD AIDS. 2016;27(10):873–81.CrossRefPubMed
40.
go back to reference Auerbach JD, et al. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefPubMedPubMedCentral Auerbach JD, et al. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS. 2015;29(2):102–10.CrossRefPubMedPubMedCentral
Metadata
Title
PrEP Implementation and Persistence in a County Health Department Setting in Atlanta, GA
Authors
Charlotte-Paige Rolle
Udodirim Onwubiko
Jennifer Jo
Anandi N. Sheth
Colleen F. Kelley
David P. Holland
Publication date
01-10-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue Special Issue 3/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02654-x

Other articles of this Special Issue 3/2019

AIDS and Behavior 3/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.